Eagle Pharmaceuticals Inc EGRX

NAS: EGRX | ISIN: US2697961082   14/11/2024
0,701 USD (-6,53%)
(-6,53%)   14/11/2024
Grafiek Eagle Pharmaceuticals Inc Grafiek Eagle Pharmaceuticals Inc

Eagle Pharmaceuticals Inc in het nieuws

9 februari 2024 · EAGLE PHARMACEUTICALS SHAREHOLDER ACTION REMINDER: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Eagle Pharmaceuticals To Contact Him Directly To Discuss Their Options · Persbericht

8 februari 2024 · EGRX Investors Have Opportunity to Lead Eagle Pharmaceuticals, Inc. Securities Fraud Lawsuit · Persbericht

2 februari 2024 · EAGLE PHARMACEUTICALS SHAREHOLDER ACTION REMINDER: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Eagle Pharmaceuticals To Contact Him Directly To Discuss Their Options · Persbericht

25 januari 2024 · EAGLE PHARMACEUTICALS INVESTOR DEADLINE APPROACHING: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Eagle Pharmaceuticals To Contact Him Directly To Discuss Their Options · Persbericht

25 januari 2024 · EGRX Investors Have Opportunity to Lead Eagle Pharmaceuticals, Inc. Securities Fraud Lawsuit · Persbericht

18 januari 2024 · EAGLE PHARMACEUTICALS INVESTOR DEADLINE APPROACHING: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Eagle Pharmaceuticals To Contact Him Directly To Discuss Their Options · Persbericht

11 januari 2024 · EAGLE PHARMACEUTICALS INVESTOR DEADLINE APPROACHING: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Eagle Pharmaceuticals To Contact Him Directly To Discuss Their Options · Persbericht

11 januari 2024 · EGRX Investors Have Opportunity to Lead Eagle Pharmaceuticals, Inc. Securities Fraud Lawsuit · Persbericht

4 januari 2024 · EAGLE PHARMACEUTICALS INVESTOR DEADLINE APPROACHING: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Eagle Pharmaceuticals To Contact Him Directly To Discuss Their Options · Persbericht

28 december 2023 · EGRX Investors Have Opportunity to Lead Eagle Pharmaceuticals, Inc. Securities Fraud Lawsuit · Persbericht

Profiel Eagle Pharmaceuticals Inc

Fabricage van farmaceutische preparaten
Farmaceutische producten: Andere
Gezondheidstechnologie
Productie

Website: www.eagleus.com

Hoofdzetel: Woodcliff Lake, New Jersey vlag Verenigde Staten

Mijn selecties